Endocrine Abstracts

Patients with adrenal insufficiency need adjustment of the hydrocortisone (HC) dose during an intercurrent illness. Current recommendation to double the daily HC dose at each occasion does not consider the non-linear dose proportionality in bioavailability i.e. doubling the dose gives less than 100% increase in exposure. We have developed an intercurrent illness dose regimen for a once daily dual release HC tablet using population pharmacokinetic (POPPK) modeling.<p class=...

There is no consensus on the best dosing regimen for glucocorticoid replacement therapy. The general intention is to individualize according to the clinical response and use the lowest possible maintenance dose without risking adrenal crisis.Aim: To survey patients with adrenal insufficiency (AI) on their glucocorticoid replacement therapy dosing regimen.Method: Patients (children and adults) were recruited via patient organization...

Objective: Few studies have determined the effects of more than 5-10 years of GH replacement in adults on body composition and metabolic parameters.Design/Patients: In this prospective, single-center, open-label study, the effects of 15 years of GH replacement on body composition and metabolic parameters were determined in 156 hypopituitary adults (93 men) with adult onset GH deficiency (GHD). Mean age was 50.5 (range 22–74) years at study start. Bo...

Objective: Few studies have determined the effects of more than 5–10 years of GH replacement in adults on bone mass and density.Design/patients: In this prospective, single-centre, open-label study, the effects of 15 years of GH replacement on bone mineral content (BMC) and bone mineral density (BMD) were determined in 126 hypopituitary adults (72 men) with adult onset GH deficiency (GHD). Mean age was 49.4 (range 22–74) years at study start. B...

Context: The effect of GH replacement in elderly GH deficient (GHD) adults on bone mineral density (BMD) is not known.Objective: In this prospective, single-centre, open-label study, the effects of 3-year GH replacement were determined in 45 GHD adults above 65 years of age and in 45 younger GHD patients with a mean age of 39.5 (S.E.M. 1.1) years. All patients had adult onset disease and both groups were comparable in terms of number of an...

Context: Little is known of the importance of previous irradiation therapy for baseline characteristics and responsiveness to GH replacement in GH deficient (GHD) adults.Objective/design/patients: In this prospective, single-centre, open-label study, the effects of 10-year GH replacement on metabolic variables and safety were determined in 18 GHD adults that had previously received pituitary irradiation therapy and 18 non-irradiated GHD patients. All pat...

Introduction: There are limited prospective safety data on glucocorticoid replacement. The aim of this study was to assess the safety and efficacy during long term treatment using a once-daily oral dual-release hydrocortisone in patients with adrenal insufficiency (AI).Methods: This is an open, multi-centre study in 71 patients with AI. Most patients were recruited from a previous controlled trial (n=53) where they had received the dual-release th...